Calidi Biotherapeutics

Calidi Biotherapeutics is a pioneering biotechnology company with a mission to find the cure for cancer. They are at the forefront of developing innovative cancer treatment options using oncolytic viruses designed to attack cancer cells. Their groundbreaking research into the therapeutic effects of stem cells has led to the development of allogeneic cell-based oncolytic platforms for the treatment of cancer and other therapy-resistant diseases.

One of their notable technologies is the off-the-shelf supply of mesenchymal stem cells (MSCs), which have been used for viral therapy applications outside of cancer treatment. Through their SNV1 product, they have achieved efficient delivery of the oncolytic virus to tumor sites, effectively potentiating the viral payload by shielding it from the patient's immune system. Calidi Biotherapeutics boasts a talented team of world-class executives, doctors, and scientists who are producing revolutionary work in the field of cancer treatment.

They have also partnered with renowned institutions like City of Hope for clinical trials evaluating their leading-edge therapeutic candidates. With recent investments and a merger agreement in place, Calidi Biotherapeutics is poised to further advance their stem cell-based platforms and revolutionize oncolytic virotherapies